Treatment of Adult Severe Traumatic Brain Injury Using Autologous Bone Marrow Mononuclear Cells
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs CEVA 101 (Primary)
- Indications Traumatic brain injuries
- Focus Therapeutic Use
- 28 Feb 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2020.
- 25 Apr 2018 New trial record
- 16 Mar 2018 This study is supported by the National Institutes of Health (NIH) and Department of Defense grant.